Gilead Sciences is acquiring Arcellx for $7.8 billion to accelerate the delivery of next-generation cancer treatments. The deal focuses on advancing a B-cell maturation antigen-directed CAR T-cell therapy currently under regulatory review for relapsed or refractory multiple myeloma.
This strategic acquisition gives Gilead full control over the lead candidate drug's development and commercialization, eliminating existing profit-sharing and milestone payments. The therapy recently received FDA acceptance for its Biologics License Application, with preliminary data suggesting it could address challenges for heavily pretreated patients.
Daniel O’Day, Chairman and CEO of Gilead, stated the intention is to "move with speed so we can make the most of [the] potential for patients with multiple myeloma."
The acquisition also includes Arcellx's proprietary technology platform, which utilizes synthetic binder domains. Kite, a Gilead company, is expected to leverage these binders to improve future CAR T-cell, bispecific therapies, and in vivo cell therapy applications across Gilead’s oncology and inflammation pipelines.
Rami Elghandour, Chairman and CEO of Arcellx, commented that "Kite is well-positioned to maximise access… The company’s commitment to be the leader in cell therapy is one I admire."
The transaction is anticipated to conclude in the second quarter of 2026, pending standard closing conditions and regulatory approvals.